Cooperative Agreement UG3DA061645
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$1.6M
Federal Agency
National Institute on Drug Abuse
Awardee
Dimerx (HPE8WDLFMG25)
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to continue the clinical development of PF614-MPAR, an opioid product with overdose protection. PF614-MPAR is a combination product that includes a trypsin-activated abuse-resistant oxycodone prodrug (PF614) and the trypsin inhibitor nafamostat, which provides overdose protection. The goal of this award is to...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $19,302,777 to Nirsum Laboratories, Inc. to accelerate the development of NRS-033, a long-acting injectable medication for opioid use disorder (OUD). The key products and services to be delivered under this award include late-stage chemistry, manufacturing, and controls (CMC) for the active pharmaceutical ingredient (API) and drug...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $4,710,576 to Mebias Discovery Inc. to develop a new chemical entity, MEB-1170, as a maintenance medication for the treatment of opioid use disorder (OUD). The project aims to evaluate the efficacy of MEB-1170 in reducing fentanyl self-administration and its safety profile, including its ability to avoid respiratory depression and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $598,312 to Addinex Technologies, Inc. to integrate and assess a closed-loop medication management system focused on opioid pain management for patients with extremity fractures being discharged from the emergency department. The system aims to reduce opioid use by integrating an opioid dispensing, monitoring, and disposal platform with a...
This Cooperative Agreement award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the clinical development of SBS-147, a first-in-class oral arylepoxamide agonist for the treatment of pain. The $3,138,031 award to Sparian Biosciences Inc., doing business as Palion Therapeutics, aims to conduct a Phase 1 safety and tolerability study as well as a Phase 2a dental pain proof-of-concept trial for SBS-147. This novel...
This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...
This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $9,275,866 to the University of North Carolina at Chapel Hill to develop small molecule compounds that engage a non-opioid G protein-coupled receptor (GPCR) in brain regions associated with the unpleasant affective aspects of pain perception. The goal is to create safer analgesics that can reduce pain...
The National Institute on Drug Abuse (NIDA) awarded a $220,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Amalgent Therapeutics, Inc. in Greenville, NC. This grant supports the development of a novel opioid adjuvant technology that aims to enhance the pain-relieving efficacy of opioid medications while mitigating risks such as abuse potential, tolerance, and neuropathic pain. The project has two key objectives: 1) investigating the mechanism by which the...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $11,811,988 in funding to The University of Texas Health Science Center at San Antonio (UTHSCSA) to continue development of the novel mu-opioid receptor antagonist Methocinnamox (MCAM) for preventing opioid relapse after detoxification. The 3-year project aims to: 1) submit an Investigational New Drug (IND) application for MCAM to prevent...
This Project Grant award of $399,536 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research by Chemregen Inc. to design, synthesize, and test non-opioid drug candidates as a new approach to combat the opioid crisis. The key objectives are to: 1) Design and synthesize lead and control compounds, characterize them chemically and pharmacologically for receptor binding, and conduct ADMET studies; and 2) Characterize human...